Almirall adds to profile as key dermatology player

Spanish skincare specialist Almirall (BME: ALM) has promised a key contribution at the International Congress of Dermatology (ICD), currently taking place in Rome, Italy.

The Barcelona-based firm is participating with two scientific symposia, a series of poster presentations and a commercial exhibition stand at the event, which is held every four years as researchers, leading dermatologists and other healthcare professionals come together to exchange knowledge, clinical practices and innovations in dermatology.

In the scientific symposia, Almirall will focus on new real-world clinical data on the efficacy and safety of Ebglyss (lebrikizumab) in atopic dermatitis and address clinical opportunities in managing difficult-to-treat psoriasis with Ilumetri/Ilumya (tildrakizumab).